- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01213030
Clinical Evaluation of the New Hypoxia Imaging Agent HX4
September 20, 2012 updated by: Yi Hui Guan, Siemens Molecular Imaging
Positron Emission Tomography (PET) with fluorine-18 fluoromisonidazole (FMISO) has been used for several years as a non invasive imaging technique to study tumor hypoxia.
Several experimental and clinical studies have indicated that FMISO uptake of tissues is correlated with tissue oxygen tension and that FMSO PET allows non-invasive differentiation between hypoxic and normoxic tumors.
Currently, FMISO-PET represents the best characterized and validated noninvasive hypoxia imaging technique.
Nevertheless, clinical studies have also shown the limitations of FMISO PET.
Accumulation of FMISO in hypoxic tumors is relatively low, resulting in a low contrast between hypoxic tumors and surrounding normal tissues.
In addition, imaging needs to be started relatively late after tracer injection (about 3 hours post-injection), when a significant percentage of the fluorine-18 label has already decayed and the count statistics of the PET images are relatively low.
Because of these limitations, FMISO PET is still only used at a few research centers, despite high clinical interest in hypoxia imaging.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Objective of the study
The aim of this study is to:
- evaluate a hypoxia imaging agent, HX4, in patients with solitary tumors (i.e., locally advanced head and neck cancer)
- gain information on bio-distribution of [F-18]HX4
- compare the PET images of [F-18] FMISO to [F-18]HX4 for resolution, signal to background ratio, and tumor/blood ratio
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shanghai, China, 200235
- PET Center, Huashan Hospital, Fudan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient may be male or female and of any race / ethnicity
- Patient is > 18 years old at the time of investigational product administration
- Patient or patient's legally acceptable representative provides written informed consent
- Patient is capable of complying with study procedures
- Patient is capable of communicating with study personnel
- Patient must have histologically confirmed stage III, or IV squamous cell carcinoma of the head and neck whose primary origin was from the oral cavity, oropharynx, hypopharynx, or larynx.
- According to the Karnofsky Performance Status Scale, the patient has a value of ≥ 60% at time of screening
Patient must have normal organ and renal function as defined:
- total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SGPT) less than or equal to 2.5 x institutional upper limits of normal
- creatinine within normal institutional limits
- BUN within normal institutional limits
- PT and PTT < 2.0 x institutional upper limits of normal
Exclusion Criteria:
- Patient is younger than 18 years old at the time of investigational product administration
- Female patient is pregnant or has a positive serum pregnancy test
- Patient is unable to remain still for duration of imaging procedure
- Patient has a history of significant renal disease
- Patient has previously received [F-18]HX4 at any time, or any other investigational product in the past thirty days.
- Patient has been involved in an investigative, radioactive research procedure within the past year
- Inadequate tumor sites or volume to allow for biopsy
- Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete and good quality data
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 10 mCi HX4
Patient will be injected with [F-18] FMISO
|
10 mCi [F18] HX4 and 10 mCi [F-18] FMISO within 7 days of each other regardless of sequence
|
ACTIVE_COMPARATOR: 10 mCi FMISO
Patient will be injected with [F-18] HX4
|
10 mCi [F18] HX4 and 10 mCi [F-18] FMISO within 7 days of each other regardless of sequence
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy of a hypoxia imaging agent, HX4, in patients with solitary tumors (i.e., locally advanced head and neck cancer)
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Resolution, signal to background ratio, and tumor/blood ratio of PET images with [F-18] FMISO and [F-18]HX4
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Yi Hui Guan, MD, PET Center, Huashan Hospital, Fudan University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (ACTUAL)
January 1, 2010
Study Completion (ACTUAL)
May 1, 2010
Study Registration Dates
First Submitted
August 14, 2009
First Submitted That Met QC Criteria
September 29, 2010
First Posted (ESTIMATE)
October 1, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
September 25, 2012
Last Update Submitted That Met QC Criteria
September 20, 2012
Last Verified
September 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HX4-FMISO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
Clinical Trials on [F-18] HX4
-
Siemens Molecular ImagingWithdrawnHead and Neck CancerUnited States
-
Siemens Molecular ImagingCompletedHead and Neck CancerUnited States
-
Siemens Molecular ImagingCompletedCervical Cancer | Head and Neck Cancer | Lung Cancer | Rectal Cancer | Liver Cancer
-
Chang Gung Memorial HospitalCompleted
-
Chang Gung Memorial HospitalCompletedFrontotemporal Dementia | Progressive Supranuclear Palsy | Alzheimer's Disease | Vascular Cognitive Impairment | Cortical Basal SyndromeTaiwan
-
Siemens Molecular ImagingCompleted
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus NeoplasmsUnited States
-
ABX advanced biochemical compounds GmbHCompletedProstate Cancer | Prostate Cancer RecurrentFrance
-
Siemens Molecular ImagingCompletedHead and Neck Cancer | Lung CancerUnited States
-
Northwell HealthCompletedNeuroendocrine TumorsUnited States